Latest News
Exelixis Releases Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma
22 October 2018 - - US-based Exelixis, Inc. (NASDAQ: EXEL) has published results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with ad...
ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with Keytruda
22 October 2018 - - US-based ImmunoGen, Inc., (NASDAQ: IMGN), a specialist in the field of antibody-drug conjugates for the treatment of cancer, has announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort ass...
Pfizer Presents Overall Survival Data from PALOMA-3 Trial of Ibrance (palbociclib) in Patients with HR+, HER2- Metastatic Breast Cancer
22 October 2018 - - US-based biopharmaceutical company Pfizer Inc. (NYSE: PFE) has released detailed overall survival data from the PALOMA-3 trial, which evaluated Ibrance (palbociclib) in combination with fulvestrant compared to placebo plus fulvest...
Opdivo in Combination with Yervoy Shows Promising Results in Patients with Advanced form of Bladder Cancer
22 October 2018 - - US-based biopharmaceutical company Bristol-Myers Squibb Company (NYSE: BMY) has published follow-up data evaluating Opdivo (nivolumab) monotherapy and Opdivo in combination with Yervoy (ipilimumab) in...
US Merck's Keytruda Showed a Complete Response Rate of Nearly 40% in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care
22 October 2018 - - US-based biopharmaceutical company Merck (NYSE: MRK) has presented results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating Keytruda, Merck's anti-PD-1 therapy, for previously treated patients with high-ris...